IntelGenx Technologies Cash Flow - Quarterly (OTCMKTS:IGXT)

Add to My Stocks
$1.21 $0.62 (33.88%) IGXT stock closing price Sep 21, 2018 (Closing)

For analyzing any company like IntelGenx Technologies from an investment perspective, its important to check the cash flow statement. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For IntelGenx Technologies profits one has to check the income statement and for IntelGenx Technologies debt one has to check the balance sheet. IntelGenx Technologies saw a cash impact of $- from the buyback of IGXT shares. The cash flow statement helps in the IntelGenx Technologies stock analysis by providing more information for evaluating changes in assets, liabilities and equities. The cash from operating activities for IntelGenx Technologies is $ 2018 Q2, which saw a decrease from previous quarter.

View and download details of IntelGenx Technologies cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-0.15M-0.23M-2.5M-1.43M-1.34M-0.35M2.2M4.06M-0.35M-0.46M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net----------
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.45M-0.43M-0.97M-0.9M-0.45M-0.22M-2.32M-2.22M-1.84M-0.29M
Acquisition Disposition of Subsidiaires-------5.23M---
Increase (Decrease) in Investments1.9M1.51M--1.21M2.32M-1.65M-3M--
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares--1.23M1.18M1.01M-----
Issuance (Repayment) of Debt Securities-0.37M-0.18M4.76M4.45M-0.35M-0.1M1.26M1.26M1.49M-
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities2.92M--0.49M-------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-0.12M-0.06M---0.01M-0.1M----
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year-2.86M4.39M5M2.05M3.5M1.14M1.52M--
Cash & Equivalents at Year End2.32M-1.59M1.63M1.17M--2.72M1.09M2.06M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

IntelGenx Technologies stock price history provides insight into historical stock price fluctuations, and IntelGenx Technologies stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • IntelGenx Technologies had a Net Change in Cash and Cash Equivalents of $- in the latest quarter 2018 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the IntelGenx Technologies stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. IntelGenx Technologies lost $-3.7M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $1.45M for IGXT till last quarter 2018 Q2 report.
  • Cash flow from financing activities shows the flow of cash between IntelGenx Technologies and its owners and creditors and was $3.09M till 2018 Q2. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For IntelGenx Technologies Cash Flow

Quarterly Cash Flow Statements For IntelGenx Technologies Corp. Peers

Alnylam Pharma cash flow, BIOCARDIA INC cash flow, Foamix cash flow, Pharmacyte Biotech cash flow, Skinvisible cash flow